Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain
Introduction: Chronic hyperkalemia has negative consequences in the medium and long term, and determines the suspension of nephro and cardioprotective drugs, such as renin–angiotensin–aldosterone system inhibitors (RAASi). There is an alternative to the suspension or dose reduction of these treatmen...
Main Authors: | Patricia de Sequera, Ramón Bover, Yoana Ivanova-Markova, Alexandra Ivanova, Almudena González-Domínguez, Marta Valls, Verónica Campos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-11-01
|
Series: | Nefrología (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2013251424000026 |
Similar Items
-
Consensus document on the management of hyperkalemia
by: Alberto Ortiz, et al.
Published: (2023-11-01) -
UNELE DILEME CLINICE IN MEDICATIA CU INHIBITORII SISTEMULUI RENINA-ANGIOTENSINA-ALDOSTERONA LA PACIENTII CU INSUFICENTA CARDIACA
by: Liuba POPESCU, et al.
Published: (2024-08-01) -
Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain
by: Roberto Alcázar-Arroyo, et al.
Published: (2024-09-01) -
Uma Situação de “Apertar o Coração”: Manejando Insuficiência Cardíaca com Fração de Ejeção Reduzida em Insuficiência Adrenal Primária
by: Matheo Augusto Morandi Stumpf, et al.
Published: (2023-08-01) -
COVID-19 e hipertensión arterial: ¿existe evidencia para suspender antagonistas del sistema renina-angiotensina-aldosterona?
by: Ignacio Villanueva Bendek, et al.
Published: (2020-04-01)